安徽海螺水泥股份有限公司 2025 年第三季度报告 证券代码：600585 证券简称：海螺水泥 安徽海螺水泥股份有限公司 2025 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会及董事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、主要财务数据 （一） 主要会计数据和财务指标 1 / 11 单位：元 币种：人民币 项目 本报告期 本报告期比上年 同期增减变动幅 度(%) 年初至报告期末 年初至报告期末 比上年同期增减 变动幅度(%) 营业收入 20,005,988,900 -11.42 61,297,773,984 -10.06 利润总额 2,600,523,482 7.65 8,436,882,329 24.03 归属于上市公司股东的净利润 1,936,632, ...

Financial Performance - The company's operating revenue for Q3 2025 was ¥422,642,823.32, a decrease of 2.48% year-on-year, and the year-to-date revenue was ¥1,213,350,806.98, down 9.40% compared to the same period last year[4]. - Total profit for Q3 2025 was ¥17,346,291.96, representing a significant decline of 76.40% year-on-year, while the year-to-date total profit was ¥110,665,618.64, down 44.51% compared to the previous year[4]. - Net profit attributable to shareholders for Q3 2025 was ¥14,798,022.56, a decrease of 75.76% year-on-year, and the year-to-date net profit was ¥91,199,107.29, down 44.30% compared to the same period last year[4]. - The basic earnings per share for Q3 2025 was ¥0.0268, down 75.81% year-on-year, while the year-to-date basic earnings per share was ¥0.1653, a decrease of 44.31% compared to the previous year[5]. - Total operating revenue for the first three quarters of 2025 was CNY 1,213,350,806.98, a decrease of 9.4% compared to CNY 1,339,284,840.18 in the same period of 2024[18]. - Net profit for the first three quarters of 2025 was CNY 108,619,300.32, a decline of 61.1% from CNY 177,904,075.06 in 2024[19]. - The net profit attributable to shareholders of the parent company was CNY 91,199,107.29, down 44.3% from CNY 163,732,739.89 in the previous year[19]. - Earnings per share for the first three quarters of 2025 was CNY 0.1653, compared to CNY 0.2968 in the same period of 2024[19]. Cash Flow - The net cash flow from operating activities for Q3 2025 was ¥60,553,091.34, down 40.78% year-on-year, and the year-to-date net cash flow was ¥71,441,961.46, a decline of 62.35% compared to the same period last year[4]. - Cash inflow from operating activities totaled $1,441,155,385.28, a decrease of 9.9% from $1,599,011,480.06 in the previous period[22]. - Net cash outflow from operating activities was $71,441,961.46, down 62.4% compared to $189,743,035.29 last year[22]. - Cash inflow from investment activities was $116,078,474.78, slightly down from $118,025,003.10[22]. - Net cash flow from investment activities improved to $52,499,590.78 from a negative $54,893,297.46[22]. - Cash inflow from financing activities was $4,355,560.00, unchanged from the previous period[23]. - Net cash outflow from financing activities increased to $70,463,488.67 from $62,363,956.24[23]. - Total cash inflow from other operating activities was $76,493,122.23, an increase of 27.3% from $60,060,861.97[22]. - Cash paid for purchasing goods and services was $775,873,849.26, a decrease of 3.4% from $803,345,709.38[22]. - Cash paid for employee compensation was $457,083,468.24, down 4.6% from $479,208,266.09[22]. Assets and Liabilities - The company's total assets at the end of Q3 2025 were ¥5,592,153,495.60, an increase of 0.69% compared to the end of the previous year[5]. - Total current assets as of September 30, 2025, amount to ¥2,357,455,297.79, an increase from ¥2,306,279,590.27 as of December 31, 2024[14]. - Total non-current assets as of September 30, 2025, are ¥3,234,698,197.81, slightly down from ¥3,247,452,611.12[15]. - Total liabilities as of the latest reporting date were CNY 1,075,653,786.62, slightly down from CNY 1,082,163,072.85[16]. - Total equity attributable to shareholders of the parent company increased to CNY 4,281,275,730.61 from CNY 4,232,115,955.48[16]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 62,941[11]. - The largest shareholder, Shanghai Jinjiang Capital Co., Ltd., holds 212,586,460 shares, accounting for 38.54% of total shares[11]. Operational Challenges - The decline in total profit and net profit was primarily attributed to the decrease in the fair value of trading financial assets and a reduction in government subsidies compared to the previous year[8]. - The company reported a significant decrease in operating income and net profit due to reduced cash inflows from vehicle sales and lower government subsidies[8]. - The company experienced a decrease in sales expenses, which were CNY 52,625,712.54 in 2025 compared to CNY 103,450,047.71 in 2024, reflecting a cost-cutting strategy[18]. Investments and Contracts - The company has signed new long-term leasing contracts, which contributed to an increase in right-of-use assets by 410.02%[9]. - The company reported a financial income of CNY 23,927,562.94 for the first three quarters of 2025, compared to CNY 16,890,571.13 in 2024[18]. - The company’s investment income for the first three quarters of 2025 was CNY 86,097,195.33, down from CNY 101,913,247.81 in the same period of 2024[18].

Financial Performance - The company's operating revenue for the third quarter was ¥586,364,920.12, representing a year-on-year increase of 3.90%[5] - The total profit for the quarter was ¥29,265,783.07, reflecting a year-on-year increase of 14.43%[5] - The net profit attributable to shareholders was ¥26,121,384.51, which is a 7.92% increase compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥19,968,335.21, down 38.58% year-on-year due to changes in product structure and market competition[9] - The basic earnings per share for the quarter was ¥0.14, an increase of 16.67% year-on-year[5] - Total operating revenue for the first three quarters of 2025 was CNY 1,666,215,763.12, a decrease of 5.95% compared to CNY 1,771,958,738.10 in the same period of 2024[23] - Net profit for the first three quarters of 2025 was CNY 80,010,980.83, a decline of 14.8% from CNY 93,780,334.44 in 2024[24] - Earnings per share for the first three quarters of 2025 was CNY 0.44, compared to CNY 0.49 in the same period of 2024[25] - Operating profit for the first three quarters of 2025 was approximately ¥99.50 million, down 12.3% from ¥113.49 million in 2024[36] - Net profit for the first three quarters of 2025 was approximately ¥89.79 million, a decline of 13.0% compared to ¥103.19 million in 2024[36] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,938,446,227.00, a decrease of 5.83% compared to the end of the previous year[6] - Total assets decreased to CNY 2,938,446,227.00 in 2025 from CNY 3,120,257,478.72 in 2024, reflecting a reduction of 5.83%[21] - Total liabilities decreased to CNY 1,438,476,661.61 in 2025 from CNY 1,655,905,033.75 in 2024, a decline of 13.14%[21] - Total liabilities decreased to CNY 1,345,505,218.72 as of September 30, 2025, compared to CNY 1,543,260,196.69 at the end of 2024[33] Cash Flow - The company reported a net cash flow from operating activities of ¥415,988,263.62 for the year-to-date, reflecting a slight increase of 0.76%[5] - Cash inflow from operating activities for the first three quarters of 2025 was CNY 1,358,074,461.02, a decrease of 12.06% compared to CNY 1,544,438,827.30 in the same period of 2024[28] - Net cash flow from operating activities for the first three quarters of 2025 was CNY 415,988,263.62, slightly up from CNY 412,864,712.18 in 2024, indicating a stable performance[28] - Cash flow from operating activities for the first three quarters of 2025 was approximately ¥415.21 million, slightly down from ¥431.09 million in 2024[39] - Cash inflow from financing activities for the first three quarters of 2025 was CNY 512,210,103.86, down from CNY 598,666,489.00 in 2024[29] Shareholder Changes - The first phase of the share transfer agreement was completed on September 30, 2025, with a total of 31,454,679 shares transferred, resulting in a new controlling shareholder, Lu Hongping, holding 19.64% of the voting rights[16] - The company plans to issue 30 million A-shares, which will increase the acquirer's shareholding to 34.73% post-issuance[15] - The second phase of the share transfer is expected to be completed by March 31, 2026, with 9,766,073 shares involved[13] - The company has signed a voting rights waiver agreement, where the previous controlling shareholders will waive their voting rights on the second phase of shares until the completion of the transfer[13] - The board of directors has elected Tu Han as the chairman, effective immediately, following the recent changes in control[17] - The company has appointed new non-independent directors, including Tu Han and Tu Jian, as part of the board restructuring following the change in control[17] Inventory and Current Assets - As of September 30, 2025, the company's total current assets amounted to approximately CNY 1.43 billion, a decrease from CNY 1.50 billion as of December 31, 2024, reflecting a decline of about 4.5%[19] - The company's inventory decreased to CNY 500.32 million from CNY 558.49 million, indicating a reduction of about 10.4%[19] - The company’s inventory as of September 30, 2025, was CNY 474,951,920.67, a decrease from CNY 525,768,416.65 at the end of 2024[31] Research and Development - The company reported a decrease in research and development expenses to CNY 55,901,379.19 in 2025 from CNY 63,049,273.55 in 2024, a reduction of 11.4%[24] - The company reported a decrease in research and development expenses to approximately ¥49.58 million in 2025 from ¥57.54 million in 2024, a reduction of 13.8%[35] Financial Expenses - The company’s financial expenses decreased significantly to approximately ¥1.41 million in 2025 from ¥23.90 million in 2024, a reduction of 94.1%[35]

重要内容提示： 公司董事会及董事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 中远海运能源运输股份有限公司 2025 年第三季度报告 证券代码：600026 证券简称：中远海能 中远海运能源运输股份有限公司 2025 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 1 / 13 中远海运能源运输股份有限公司 2025 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 2 / 13 单位：元 币种：人民币 项目 本报告期 上年同期 本报告期比 上年同期增 减变动幅度 (%) 年初至报告期末 上年同期 年初至报告 期末比上年 同期增减变 动幅度(%) 调整前 调整后 调整后 调整前 调整后 调整后 营业收入 5,466,168,242.83 5,492,927,694.45 5,6 ...

Financial Performance - The company's operating revenue for the third quarter reached ¥121,827,785.95, representing a year-on-year increase of 24.04%[4] - The total profit for the quarter was ¥122,380.86, reflecting an 18.57% increase compared to the same period last year[4] - The net profit attributable to shareholders was ¥122,380.86, also up by 18.57% year-on-year[4] - The net profit attributable to shareholders, excluding non-recurring gains and losses, was a loss of ¥995,996.89, with a year-to-date loss of ¥2,047,145.11[4] - Total operating revenue for the first three quarters of 2025 reached ¥358,993,641.34, a 20.2% increase from ¥298,505,605.07 in the same period of 2024[18] - Net profit for the first three quarters of 2025 was ¥1,291,415.28, compared to ¥1,233,041.09 in the same period of 2024, reflecting a slight increase of 4.7%[20] - The total comprehensive income for the first three quarters of 2025 was ¥1,291,415.28, compared to ¥1,233,041.09 in 2024, indicating stable performance[20] Cash Flow and Assets - The cash flow from operating activities showed a net outflow of ¥34,603,458.29 for the year-to-date period[5] - The company's cash and cash equivalents are reported at ¥200,406,589.33, down from ¥254,014,000.64[12] - Cash and cash equivalents at the end of the period stood at ¥123,322,291.44, down from ¥163,781,736.54 at the end of the same period in 2024[22] - The company's total assets as of September 30, 2025, amount to ¥1,207,745,656.06, an increase from ¥1,145,725,584.29 as of December 31, 2024[13] - Current assets total ¥732,009,525.05, slightly down from ¥737,519,204.73 in the previous period[13] - Total liabilities amount to ¥437,147,659.17, compared to ¥376,868,709.87 in the previous period, showing an increase of about 15.9%[14] Shareholder Information - The net profit attributable to shareholders, excluding non-recurring gains and losses, increased by 53.03% compared to the same period last year[9] - The year-to-date net profit attributable to shareholders, excluding non-recurring gains and losses, increased by 79.52% compared to the same period last year[9] - The total number of common shareholders at the end of the reporting period is 139,437[11] - The largest shareholder, Chen Zhi Automobile Technology Group Co., Ltd., holds 398,067,580 shares, representing 37.25% of total shares[11] - The company's equity attributable to shareholders is reported at ¥770,597,996.89, a slight increase from ¥768,856,874.42[14] Expenses and Investments - Total operating costs increased to ¥365,242,766.70, up 17.8% from ¥310,186,965.33 year-over-year[18] - The company incurred a total of ¥5,245,637.17 in selling expenses, down from ¥7,815,478.66 in the previous year, suggesting improved cost management[18] - Research and development expenses for the first three quarters of 2025 were ¥8,365,576.65, an increase from ¥7,752,294.72 in 2024, indicating a focus on innovation[18] - The company reported a net cash outflow from investing activities of ¥40,808,288.00 for the first three quarters of 2025, slightly higher than the outflow of ¥40,523,121.75 in 2024[22] Future Outlook and Strategy - Future outlook indicates a projected revenue growth of 10% for Q4 2025[23] - The company is investing 50 million yuan in new product development for the upcoming year[23] - Market expansion plans include entering two new provinces by Q2 2026[23] - The company is exploring potential acquisitions to enhance its market position[23] - New strategies include a focus on digital transformation to improve operational efficiency[23] - R&D efforts are being increased by 25% to support innovation initiatives[23] - The company aims to achieve a gross margin of 30% by the end of 2025[23]

Financial Performance - The company's revenue for Q3 2025 was CNY 90,047,095, representing a year-on-year increase of 2.15%[3] - Total profit for the period reached CNY 22,986,189.68, a significant increase of 189.84% compared to the same period last year[3] - Net profit attributable to shareholders was CNY 18,841,383.45, up 137.06% year-on-year[3] - The basic earnings per share for the quarter was CNY 0.17, reflecting a 142.86% increase compared to the previous year[4] - For the period ending September 30, 2025, the company achieved operating revenue of RMB 262.15 million, a year-on-year increase of 7.20%[12] - The company reported a net profit attributable to shareholders of RMB 34.87 million, representing a year-on-year growth of 4.78%[12] - Net profit for the first three quarters of 2025 was ¥34,871,734.73, compared to ¥33,280,179.63 in 2024, indicating a growth of 4.8%[23] - Basic earnings per share for the first three quarters of 2025 increased to CNY 0.32 from CNY 0.30 in the same period of 2024[24] Research and Development - Research and development expenses totaled CNY 18,678,844.16, accounting for 20.74% of revenue, a decrease of 2.63 percentage points from the previous year[4] - Total R&D and sales expenses for the period amounted to RMB 117.40 million, reflecting a year-on-year increase of 15.52%[13] - Research and development expenses increased to ¥62,726,452.45 in 2025 from ¥54,053,304.42 in 2024, marking a rise of 16.0%[22] Cash Flow and Investments - The net cash flow from operating activities for the year-to-date was CNY 25,656,263.61, down 42.68% year-on-year[3][8] - The company experienced a decrease in cash flow due to increased supplier payments and higher employee compensation costs[8] - Cash inflow from operating activities for the first three quarters of 2025 was CNY 319,747,275.41, up from CNY 292,818,153.59 in 2024, representing an increase of approximately 9.1%[26] - Net cash flow from operating activities decreased to CNY 25,656,263.61 in 2025 from CNY 44,759,014.62 in 2024, a decline of about 42.6%[26] - Cash inflow from investment activities for the first three quarters of 2025 was CNY 167,491,919.38, significantly lower than CNY 627,501,475.69 in 2024, indicating a decrease of approximately 73.3%[27] - Net cash flow from investment activities was negative CNY 278,618,897.17 in 2025, compared to negative CNY 33,642,507.38 in 2024, reflecting a worsening investment position[27] - Cash inflow from financing activities in 2025 was CNY 110,000,000.00, compared to CNY 83,435,968.00 in 2024, showing an increase of about 31.9%[27] - Net cash flow from financing activities improved to CNY 31,692,999.43 in 2025 from negative CNY 80,492,649.85 in 2024, indicating a positive shift in financing[27] - The ending balance of cash and cash equivalents as of September 2025 was CNY 73,906,293.02, compared to CNY 64,907,168.79 in 2024, an increase of approximately 13.8%[27] - The company reported a total cash outflow from operating activities of CNY 294,091,011.80 in 2025, up from CNY 248,059,138.97 in 2024, reflecting increased operational expenditures[26] Shareholder Information - The largest shareholder, Suqian Qiliang Enterprise Management Co., Ltd., holds 39.76% of the shares, while Mr. Xiong Wei directly holds 12.95%[11] - The company completed the purchase of 378,088 shares under the 2025 employee stock ownership plan, representing 0.34% of the total share capital[14] - The company executed the repurchase and cancellation of 179,251 shares from the 2022 restricted stock incentive plan, reducing total share capital to 110,185,630 shares[15] Assets and Liabilities - The company's total assets increased by 4.40% to CNY 1,048,658,785.14 compared to the end of the previous year[4] - Current liabilities totaled ¥148,549,185.86, up from ¥109,081,796.41, reflecting a significant increase of 36.2%[18] - The total equity attributable to shareholders reached ¥877,513,055.24, compared to ¥861,332,259.36, showing an increase of 1.8%[19] - The company’s financial assets held for trading amounted to ¥319,644,952.06, compared to ¥60,747,521.13 in the previous period, indicating a substantial increase[17] - The company’s long-term equity investments decreased to ¥3,918,571.75 from ¥4,439,628.35, a decline of 11.7%[17] Strategic Initiatives - The company is focusing on technological breakthroughs and enhancing product competitiveness as part of its strategic initiatives[13] - The company participated in government research projects, leading to the recognition of deferred income as other income during the reporting period[8] Profitability Metrics - The company reported a gross profit margin of approximately 2.9% for the first three quarters of 2025, compared to 7.2% in the same period of 2024[22]

Financial Performance - The company's operating revenue for the third quarter was ¥931,628,491.33, representing a year-on-year increase of 16.60%[4] - The total profit for the period was ¥110,661,415.02, which is an increase of 25.34% compared to the same period last year[4] - The net profit attributable to shareholders was ¥58,651,470.56, showing a decrease of 30.60% year-on-year[4] - The basic earnings per share for the quarter was ¥0.0155, down 27.23% from the previous year[5] - The weighted average return on equity decreased to 0.3611%, a drop of 0.13 percentage points compared to the previous year[5] - The company reported a significant decline in net profit for the year-to-date period, with a decrease of 55.89% compared to the same period last year[4] - Total operating revenue for the first three quarters of 2025 was CNY 2,621,930,355.86, a decrease of 16.7% compared to CNY 3,150,858,656.23 in the same period of 2024[25] - Operating profit for the first three quarters of 2025 was CNY 188,654,259.53, down 40.1% from CNY 314,894,338.54 in 2024[27] - Net profit attributable to shareholders of the parent company for the first three quarters of 2025 was CNY 113,184,163.75, a decline of 55.8% compared to CNY 256,606,533.80 in 2024[27] - The total comprehensive income for the first three quarters of 2025 was CNY 91,291,967.92, a significant decrease from CNY 242,177,498.77 in 2024[28] Assets and Liabilities - The total assets at the end of the period were ¥20,550,653,181.01, reflecting a slight increase of 0.88% from the end of the previous year[5] - The total assets of the company as of September 30, 2025, amounted to RMB 20,550,653,181.01, an increase from RMB 20,371,965,197.78 at the end of 2024[20]. - The company’s current liabilities increased, with short-term borrowings rising to RMB 788,602,760.79 from RMB 540,804,238.65, indicating a growth of approximately 45.9%[21]. - Total liabilities increased to CNY 3,056,378,110.05 in 2025 from CNY 2,877,906,171.22 in 2024, representing a growth of 6.2%[23] Cash Flow - The cash flow from operating activities was negative at -¥239,516,599.07, a decline of 201.20% compared to the same period last year[4] - Cash received from sales of goods and services was CNY 2,521,329,196.90 in the first three quarters of 2025, down 22.0% from CNY 3,233,097,961.39 in 2024[30] - Operating cash inflow totaled $2,820,780,562.79, a decrease from $3,597,704,121.14 in the previous period[31] - Net cash flow from operating activities was negative at -$530,275,710.34, compared to a positive $558,245,580.80 last year[31] - The company reported a total cash outflow from operating activities of $3,351,056,273.13, compared to $3,039,458,540.34 previously[31] - Total cash outflow from investment activities was $3,633,529,838.13, a decrease from $3,764,726,959.41[31] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 204,420, with the largest shareholder holding 37.86% of the shares[12] - The company plans to distribute a cash dividend of RMB 0.02 per share, totaling RMB 75.53 million, based on a total share base of 3,776,597,903 shares after accounting for repurchased shares[16]. - The total equity attributable to shareholders of the parent company was CNY 16,192,185,283.75 in 2025, slightly up from CNY 16,170,077,933.65 in 2024[23] Investments and Projects - The company is undertaking a capacity transfer and renovation project at its subsidiary, Fushun Carbon, which includes a plan to construct a 30,000-ton ultra-high-power graphite electrode project[17]. - The company’s long-term equity investments decreased slightly to RMB 6,814,753,607.88 from RMB 6,832,955,594.88, a decline of about 0.27%[21]. - The company’s inventory as of September 30, 2025, was RMB 1,520,020,697.83, down from RMB 1,544,825,414.07, reflecting a decrease of approximately 1.6%[20]. Research and Development - Research and development expenses for the first three quarters of 2025 were CNY 49,833,021.39, a decrease of 15.0% compared to CNY 58,680,151.53 in 2024[26]

Financial Performance - For the first nine months of 2025, Shanghai Pharmaceuticals achieved a revenue of RMB 215.07 billion, representing a year-on-year growth of 2.60%[11] - The net profit attributable to shareholders for the same period was RMB 5.147 billion, a year-on-year increase of 26.96%, primarily due to a one-time special gain from changing accounting treatment for a joint venture[11] - The company's total profit for the period was CNY 1.48 billion, a decrease of 18.94% compared to the previous year[22] - The net profit attributable to shareholders was CNY 688.20 million, down 38.13% year-on-year[22] - The company's total profit for the first three quarters was ¥8.30 billion, up from ¥6.64 billion, reflecting an increase of approximately 25%[38] - Net profit for the first three quarters of 2025 was ¥5.99 billion, compared to ¥5.02 billion in 2024, marking an increase of approximately 19.2%[39] - The basic earnings per share rose to ¥1.39 from ¥1.09, indicating a growth of about 27.5%[39] Research and Development - Research and development expenses for the first nine months amounted to RMB 1.729 billion, accounting for 9.52% of the pharmaceutical manufacturing revenue[12] - The company has 57 new drug candidates in clinical trials, including 45 innovative drugs, with significant progress in various projects[12] - The BCD-085 project, an innovative monoclonal antibody, has submitted a new drug application for ankylosing spondylitis during the reporting period[12] - The company completed patient enrollment for the Phase III clinical trial of the traditional Chinese medicine product, Shenqi Sharuang Wan, aimed at treating cervical spondylotic myelopathy[13] - Research and development expenses were reported at ¥1.52 billion, slightly down from ¥1.62 billion, indicating a decrease of about 6.5%[38] - Research and development expenses decreased to CNY 270,894,446.73 in 2025 from CNY 419,246,826.18 in 2024, reflecting a reduction of approximately 35.3%[49] Business Segments - The company's pharmaceutical business achieved a revenue of CNY 73.48 billion in the current reporting period, representing a year-on-year increase of 4.65%[22] - The innovative drug business generated sales of CNY 40.7 billion, with a year-on-year growth of over 25%[19] - The import agency business reported sales of CNY 27.6 billion, reflecting a year-on-year increase of over 14%[19] - The company has 51 products in the rare disease treatment field, covering 67 rare disease conditions[18] - The company is actively participating in building a rare disease prevention and treatment ecosystem, enhancing drug accessibility[18] Assets and Liabilities - The total assets at the end of the reporting period were CNY 236.75 billion, an increase of 7.02% from the previous year[22] - The company's current assets totaled RMB 183.93 billion, up from RMB 171.82 billion in the previous year, indicating a year-over-year increase of about 7.1%[33] - The total liabilities reached RMB 147.12 billion, compared to RMB 137.47 billion in the previous year, reflecting an increase of approximately 7.3%[35] - The company's cash and cash equivalents stood at RMB 36.73 billion, slightly up from RMB 35.74 billion, showing a growth of about 2.8%[33] - The total equity of the company reached RMB 89.62 billion, an increase from RMB 83.74 billion, representing a growth of about 7.5%[35] - The total liabilities increased to approximately $27.4 billion in 2025 from $25.8 billion in 2024, suggesting a rise in financial obligations[46] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 92,942[28] - The top ten shareholders collectively hold 1,427,235,837 shares, accounting for 38.487% of the total share capital[30] - HKSCC NOMINEES LIMITED is the largest shareholder with 918,240,949 shares, representing 24.761% of the total[28] - Shanghai Pharmaceutical (Group) Co., Ltd. holds 716,516,039 shares, which is 19.322% of the total[28] - The total share capital of the company at the end of the reporting period was 3,708,361,809 shares, including 2,789,289,105 A shares and 919,072,704 H shares[30] Cash Flow and Investments - Cash flow from operating activities generated a net amount of ¥2.35 billion, down from ¥2.78 billion in the previous year, a decrease of approximately 15.4%[41] - Cash inflow from investment activities significantly increased to ¥52.81 billion, compared to ¥19.35 billion in the same period last year, representing a growth of approximately 173.5%[41] - The company reported an investment income of ¥3.37 billion, a substantial increase from ¥343.49 million in the previous year[38] - The cash flow from operating activities showed a net outflow of CNY -391,042,716.21 in 2025, worsening from CNY -224,559,735.50 in 2024[53] - The cash and cash equivalents at the end of the period were CNY 6,980,854,073.85 in 2025, down from CNY 8,234,133,720.99 in 2024, indicating a decrease of approximately 15.2%[54] Corporate Recognition and ESG - Shanghai Pharmaceuticals has been recognized as one of the top ten enterprises in the "2024 Annual China Pharmaceutical Industry Main Business Revenue Top 100" list[11] - The MSCI ESG rating for the company has been upgraded to AA, reflecting its strong performance in environmental, social, and governance aspects[11]

Financial Performance - Operating revenue for Q3 2025 was CNY 11,229,103,717.57, a decrease of 42.22% compared to the same period last year[3] - Total profit for the quarter was CNY 33,619,281.19, down 97.61% year-on-year[3] - Net profit attributable to shareholders was CNY 38,721,607.87, reflecting a 96.78% decline compared to the previous year[3] - The company's operating revenue for the reporting period decreased by 43.81%, primarily due to a reduction in coal volume and price, as well as a decline in trading business revenue[9] - The net profit attributable to shareholders for the reporting period was down 74.14%, significantly impacted by the dual decline in coal production and prices[9] - The company reported a decrease in total profit of 76.17 million for the reporting period, reflecting ongoing challenges in the coal market[9] - The net profit for the first three quarters of 2025 is CNY 795,694,845.83, a decrease of 79.93% compared to CNY 3,960,929,403.30 in the same period of 2024[19] - The basic earnings per share for the reporting period was -74.68, indicating a substantial loss compared to the previous period[9] - The basic earnings per share for the current period is CNY 0.40, down from CNY 1.58 in the previous period[20] Cash Flow and Liquidity - The net cash flow from operating activities for the year-to-date was CNY 3,856,415,347.37, a decrease of 50.49%[3] - The net cash flow from operating activities for the reporting period was -50.49 million, mainly due to decreased sales revenue from coal and coke[9] - The net cash flow from operating activities for the first three quarters of 2025 is CNY 3,856,415,347.37, a decline of 50.5% compared to CNY 7,789,008,932.08 in 2024[21] - The company's cash and cash equivalents decreased from 4.28 billion to 3.03 billion, reflecting a significant reduction in liquidity[13] - The cash and cash equivalents at the end of the period are CNY 2,248,661,905.72, down from CNY 4,814,995,237.93 at the end of 2024[22] - The net cash flow from financing activities for the reporting period was 111.11 million, mainly due to an increase in interest-bearing liabilities[9] - The net cash flow from financing activities for the first three quarters of 2025 is CNY 414,283,578.33, a recovery from -CNY 3,729,753,624.35 in 2024[22] Assets and Liabilities - Total assets at the end of the reporting period were CNY 89,255,788,210.26, an increase of 1.72% from the end of the previous year[4] - Total liabilities amounted to CNY 43,467,383,993.58, up from CNY 40,869,180,045.77 in the previous year, representing an increase of approximately 6.5%[15] - Shareholders' equity attributable to the company decreased by 2.34% to CNY 41,398,678,143.93 compared to the end of last year[4] - The equity attributable to shareholders of the parent company was CNY 41,398,678,143.93, down from CNY 42,388,718,698.68 in the previous year, reflecting a decrease of about 2.3%[16] Inventory and Borrowings - Inventory decreased by 39.48%, primarily due to the disposal of a subsidiary and reduced coal inventory[8] - Short-term borrowings increased by 106.57%, indicating a rise in the company's short-term financing needs[8] - Long-term borrowings increased by 98.53 million, primarily due to the company securing additional project loans[9] Revenue and Costs - Total operating revenue for the first three quarters of 2025 was CNY 31,924,953,670.15, a decrease from CNY 56,785,931,751.93 in the same period of 2024, representing a decline of approximately 43.8%[18] - Total operating costs for the first three quarters of 2025 amounted to CNY 31,005,772,130.29, down from CNY 52,254,045,046.87 in 2024, indicating a reduction of about 40.6%[18] - Operating income for the first three quarters of 2025 was CNY 31,841,216,698.03, compared to CNY 56,668,894,450.53 in 2024, reflecting a decrease of approximately 43.9%[18] Other Financial Metrics - Non-recurring gains and losses totaled CNY 11,552,900.33 for the quarter, significantly lower than the previous year's amount[7] - Research and development expenses for the first three quarters of 2025 totaled CNY 1,495,025,405.21, slightly down from CNY 1,639,697,851.42 in 2024, showing a decrease of about 8.8%[18] - Financial expenses for the first three quarters of 2025 were CNY 364,740,623.51, compared to CNY 406,637,613.14 in 2024, indicating a decline of approximately 10.3%[18] - The total comprehensive income attributable to the parent company's owners for the first three quarters of 2025 is CNY 1,070,337,167.78, compared to CNY 4,139,229,732.33 in 2024[20]

Revenue and Profit - Revenue for the third quarter reached ¥621,879,591.47, an increase of 33.13% compared to the same period last year[4] - Total profit for the third quarter was -¥101,131,912.31, with a year-to-date total profit of -¥550,700,575.38[4] - Net profit attributable to shareholders for the third quarter was -¥101,131,912.31, and year-to-date net profit was -¥550,700,575.38[4] - Total operating revenue for the first three quarters of 2025 reached ¥1,719,833,029.78, a significant increase of 42.2% compared to ¥1,208,874,280.23 in the same period of 2024[18] - The company reported a net loss of ¥550,700,575.38 for the first three quarters of 2025, an improvement from a net loss of ¥1,071,426,638.90 in the same period of 2024[19] - The basic and diluted earnings per share improved to -¥1.01 from -¥1.99 year-over-year[19] Research and Development - Research and development expenses totaled ¥243,367,673.06 for the third quarter, a decrease of 29.90% year-over-year[5] - R&D expenses accounted for 39.13% of revenue in the third quarter, down 43.63 percentage points from the previous year[5] - Research and development expenses decreased to ¥890,583,907.36, down from ¥1,153,407,440.34 year-over-year[18] Assets and Liabilities - Total assets increased to ¥5,977,129,884.12, reflecting an 8.70% increase from the end of the previous year[5] - The company reported current assets totaling approximately RMB 2.72 billion, an increase from RMB 2.29 billion at the end of the previous period[16] - Total assets reached approximately RMB 5.98 billion, compared to RMB 5.50 billion at the end of the previous period[16] - The total liabilities increased to ¥3,657,046,820.48, up from ¥3,512,317,547.88 year-over-year[17] - The company’s total liabilities include short-term borrowings of approximately RMB 1.07 billion, slightly down from RMB 1.08 billion[16] Shareholder Information - Total number of common shareholders at the end of the reporting period is 15,267, with 15,248 A-share shareholders and 19 H-share shareholders[15] - The company has a total of 208,569,228 shares held by HKSCC NOMINEES LIMITED, representing 37.01% of the total shares[13] - The second largest shareholder, Yantai Rongda Venture Capital Center, holds 102,381,891 shares, accounting for 18.17%[13] Cash Flow and Financing - Net cash flow from operating activities improved to ¥217,057,433.94, compared to a net outflow of ¥835,103,066.88 in the first three quarters of 2024[22] - Cash and cash equivalents amounted to RMB 1.07 billion, up from RMB 762.49 million in the previous period[16] - Cash and cash equivalents at the end of the period increased to ¥1,067,390,134.52, compared to ¥662,006,223.96 at the end of the same period in 2024[22] - The company generated ¥2,117,271,291.07 in cash inflows from financing activities, compared to ¥1,316,625,345.48 in the same period of 2024[22] Strategic Developments - The company expects to benefit from a licensing agreement with Vor Bio, which will provide exclusive rights for the development and commercialization of its proprietary drug outside of Greater China[10] - The increase in revenue is attributed to higher sales of injectable drugs, specifically TaiTasi and VidiXimab[10] - The company reported a significant reduction in clinical trial costs due to the licensing agreement, contributing to a decrease in overall losses[10] Investments and Inventory - The company has invested RMB 535.49 million in construction projects, an increase from RMB 283.23 million previously[16] - The company’s inventory stands at RMB 657.58 million, showing a slight decrease from RMB 659.37 million[16]